Answers are grounded in this paper and cite their sources.
Comparative study reveals enhanced cardiac action potentials and arrhythmia risks with temperature changes in ion channels, suggesting implications for drug safety.
Cardiac ion channel activity is crucial for generating cardiac action potentials with proper timing and duration. Drug-induced impairment of these ion channels can cause abnormal cardiac activity, including QT interval prolongation, ventricular arrhythmia, and in severe cases, sudden death. These adverse effects are among the leading reasons for drug withdrawal from the market or the denial of regulatory approval for new therapeutic candidates. Using the temperature control feature of the QPatch and Qube system, we investigated the effects of temperature on K v 11.1 (hERG), Ca v 1.2, and Na v 1.5 voltage-gated ion channels. When the temperature was set to physiological temperature conditions (35°C), a consistent change in channel kinetics was observed compared to room temperature conditions at 25°C in both instruments. The IC 50 values of hERG channel blockers dofetilide, moxifloxacin, and ondansetron were reduced at 35°C, demonstrating increased potency with higher temperature. For state-dependent inhibitors E-4031 and dofetilide, the enhanced IC 50 potency was likely due to the compound’s effect manifesting more quickly at higher temperatures, demonstrating the importance of temperature in accurate measurements. Further optimization of whole-cell parameters specifically on the QPatch system permitted stable recordings at 35°C with physiological internal solutions for upward of 45 mins, allowing the completion of six-point dose response curves for improved accuracy in IC 50 measurements of tonic and state-dependent inhibitiors.
No takes yet. Share an insight, caveat, or question.
Nagy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: